Second-generation large-diameter head (LDH) MoM THA and HRA gained popularity at the beginning of the 21st century (FAR, AOANJRR [@CIT0001], NJR [@CIT0016]). Metal particles emanate as a result of corrosion and wear of metal-on-metal (MoM) hip implants and can disseminate throughout the body. These particles can be found in several organs including lymphatic tissue, bone marrow, liver, and spleen (Case et al. [@CIT0004], Shea et al. [@CIT0027], Urban et al. [@CIT0031], Shimmin and Back [@CIT0028]). Metal debris from hip implants has been associated with chromosomal aberrations and DNA damage (Case et al. [@CIT0005], Bonassi et al. [@CIT0002], Daley et al. [@CIT0007], Polyzois et al. [@CIT0024], Sarhadi et al. [@CIT0026]). Wear particles are released both from MoM and conventional metal-on-polyethylene (MoP) bearings and from the trunnion of MoM THA (Pastides et al. [@CIT0022]). However, the risk of cancer was not increased after conventional MoP THA or after earlier used first-generation MoM THA (Visuri et al. [@CIT0032], [@CIT0035]).

Previous studies have found no increase in the overall risk of cancer after second-generation MoM hip arthroplasty in the short term when compared with other bearing types (Mäkelä et al. [@CIT0014], Smith et al. [@CIT0029], Brewster et al. [@CIT0003], Lalmohamed et al. [@CIT0011]). However, follow-up time in these studies is relatively short as cancer takes years to develop. A recent meta-analysis could not find causative relationship between second-generation MoM implants and cancer risk (Christian et al. [@CIT0006]). At the same time, a previous Finnish study reported an increased incidence of basalioma and soft tissue sarcoma in patients treated with MoM implants compared with patients treated with non-MoM implants (Mäkelä et al. [@CIT0015]). Sarcoma is a severe, life-threatening disease and due to these earlier findings we felt obligated to update our data with longer follow-up.

We have now updated our earlier results on risk of cancer (Mäkelä et al. [@CIT0014], [@CIT0015]) in patients treated with primary MoM hip implants compared with patients treated with primary non-MoM THAs and the general Finnish population in midterm follow-up, specifically the risk of sarcoma, basalioma, and skin melanoma.

Patients and methods {#s0002}
====================

In Finland virtually all cancer cases are recorded in the population-based Finnish Cancer Registry (Teppo et al. [@CIT0030], Pukkala et al. [@CIT0025]) and 98% of primary total hip implants are recorded in the Finnish Arthroplasty Register (FAR). LDH MoM THAs and hip HRAs performed in Finland between 2001 and 2010 were extracted from the FAR and formed the MoM cohort. Patients who underwent metal-on-polyethylene, ceramic-on-polyethylene, or ceramic-on-ceramic THA during the study period formed the non-MoM reference cohort. All of these study subjects were followed-up until December 31, 2014 for emigration and vital status via the Population Registry, and for cancer incidence via Finnish Cancer Registry through a personal identity code. None of the patients were lost to follow-up. While forming the study population we included the first hip implant in every patient. If a patient received another hip implant later, only those who had similar bearings in both sides were included.

There were 10,728 patients in the MoM cohort and 18,235 patients in the non-MoM THA cohort included in this study; 46% of the patients were men ([Tables 1](#t0001){ref-type="table"} and [2](#t0002){ref-type="table"}). The number of person-years at follow up was 79,521 for the MoM cohort and 152,358 for the non-MoM cohort. Of all our patients 497 (4.6%) had bilateral MoM implants. The mean follow-up was 7.4 years (0--14) in the MoM cohort and 8.4 years (0--14) in the non-MoM cohort.

###### 

Number of patients (n) according to age at operation, and number of person-years (PY) according to the age at follow-up. The non-metal-on-metal cohort consisted of implants with metal-on-polyethylene, ceramic-on-polyethylene, and ceramic-on-ceramic bearing surfaces

           Metal-on-metal cohort   Non-metal-on-metal cohort   Total                                                                           
  -------- ----------------------- --------------------------- ------- -------- ------- -------- -------- -------- -------- --------- -------- ---------
  0--9     1                       1                           --      --       --      --       --       --       1        1         --       --
  10--19   5                       16                          3       16       --      --       --       --       5        16        3        16
  20--29   25                      136                         16      69       4       17       7        29       29       153       23       98
  30--39   159                     558                         67      309      30      119      20       116      189      677       87       425
  40--49   741                     3,746                       471     2,078    143     730      157      578      884      4,476     628      2656
  50--59   2,277                   11,787                      1,643   8,578    850     3,880    922      4,416    3,127    15,667    2,565    12,994
  60--69   2,257                   19,652                      1,581   14,090   2,260   13,980   2,739    16,099   4,517    33,632    4,320    30,189
  70--79   763                     9,403                       594     6,773    3,044   25,854   5,397    39,047   3,807    35,257    5,991    45,820
  80--     65                      1,276                       48      1,036    698     13,610   1,953    33,884   763      14,886    2,001    34,920
  Total    6,293                   46,573                      4,423   32,948   7,029   58,190   11,195   94,168   13,322   104,763   15,618   127,116

PY: person-years

###### 

Baseline characteristics for the metal-on-metal cohort and for the non-metal-on-metal cohort

  --------------------------------- ------------------------ ----------------------------
  Factor                            Metal-on- metal cohort   Non-metal-on- metal cohort
  Mean age (SD)                     59 (10)                  71 (9)
  Number of women, n (%)            4,426 (41)               11,202 (61)
  Primary osteoarthritis, n (%)     9,901 (92)               17,683 (97)
  Secondary osteoarthritis, n (%)   827 (8)                  552 (3)
  --------------------------------- ------------------------ ----------------------------

Statistics {#s0003}
==========

For both cohorts (MoM and non-MoM) the person-years at risk were calculated within stratification of sex, calendar period (2001--05 and 2006--10), 5-year age groups, and follow-up time (\< 2, 2--5, and \>5 years since the operation). The expected number of each type of cancer within each stratum was calculated by multiplying the person-years in the stratum by the stratum's age, sex, and calendar-period-specific cancer incidence rate for the Finnish population. The total expected numbers of cancers were summed over the strata. The cancer risk relative to the Finnish population, i.e., standardized incidence ratio (SIR), was expressed as the ratio of observed to expected number of cases. For the 95% confidence intervals (CI), we assumed that the number of observed cases followed a Poisson distribution. The study population and detailed information on the implant types have been presented in detail in earlier publications (Mäkelä et al. [@CIT0014], [@CIT0015]).

Poisson regression analysis was used to estimate the relative cancer risk between the MoM and non-MoM cohorts for soft tissue sarcomas, melanoma and basalioma. Soft-tissue sarcoma and basalioma were chosen for Poisson regression due to the earlier results of Mäkelä et al. ([@CIT0014], [@CIT0015]) and skin melanoma due to earlier results with conventional THA (Visuri et al. [@CIT0033], Onega et al. [@CIT0020]). The risk estimate (incidence rate ratio) was adjusted for age (0--49,50--59, 60--69, 70--79, 80+) and follow-up time (\< 2, 2--5, and \>5 years since the operation). Poisson regression analysis was checked for over-dispersion. The level of statistical significance was set at p \< 0.05.

Ethics, funding, and potential conflicts of interest {#s0004}
====================================================
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Results {#s0005}
=======

The overall risk of cancer in patients treated with MoM hip implants was slightly lower than in the general Finnish population (SIR 0.9, 95% CI 0.9--1.0) ([Table 3](#t0003){ref-type="table"}).

###### 

Observed numbers of cancer cases, the expected numbers of cancer cases approximated from the Finnish population, and standardized incidence ratios with 95% confidence intervals---according to site---are given for the metal-on-metal cohort and for the non-metal-on-metal cohort. The latter cohort consisted of implants with metal-on-polyethylene, ceramic-on-polyethylene, and ceramic-on-ceramic bearing surfaces

                         Metal-on-metal cohort   Non-metal-on-metal cohort                                                                          
  ---------------------- ----------------------- --------------------------- ------ ----------------- ------ ------ ------ ------ ----------------- ------
  All sites              915                     973                         0.9    0.9--1.0          9      2851   2852   1.0    1.0--1.0          16
  Stomach                23                      21                          1.1    0.7--1.7          0.2    75     74     1.0    0.8--1.3          0.4
  Colon                  48                      55                          0.87   0.6--1.2          0.4    187    199    0.9    0.8--1.1          1
  Lung                   61                      95                          0.64   0.5--0.8**^a^**   0.6    203    260    0.78   0.7--0.9**^a^**   1
  Corpus uteri           24                      22                          1.1    0.7--1.6          0.2    78     82     1.0    0.8--1.2          0.4
  Prostate               239                     216                         1.1    1.0--1.2          2      478    461    1.0    1.0--1.1          3
  Kidney                 31                      29                          1.1    0.7--1.5          0.3    83     82     1.0    0.8--1.2          0.5
  Bladder                32                      41                          0.8    0.5--1.1          0.3    131    128    1.0    0.9--1.2          0.7
  Soft-tissue sarcoma    8                       6                           1.4    0.6--2.8          0.07   20     17     1.2    0.7--1.8          0.1
  Non-Hodgkin lymphoma   37                      38                          1.0    0.7--1.4          0.3    118    108    1.1    0.9--1.3          0.7
  Hodgkin lymphoma       2                       2                           0.9    0.1--3.1          0.02   3      4      0.7    0.1--2.0          0.02
  Multiple myeloma       13                      12                          1.1    0.6--1.8          0.1    36     41     0.9    0.6--1.2          0.2
  Leukemia               17                      18                          1.0    0.6--1.5          0.2    60     58     1.0    0.8--1.3          0.3
  Melanoma               38                      36                          1.1    0.8--1.5          0.4    105    87     1.2    1.0--1.5          0.6
  Basalioma              306                     246                         1.2    1.1--1.4**^a^**   3      913    878    1.0    1.0--1.1          5

Obs: observed number of cancer cases; Exp: expected number of cancer cases based on cancer incidence in the comparable Finnish population; SIR: standardized incidence ratio; CI: confidence interval; % of cancer: the percentage of patients diagnosed with a certain cancer during the follow-up.

**^a^**p \< 0.001

There were 8 soft-tissue sarcomas in the MoM cohort during the follow-up period (SIR 1.4, CI 0.6--2.8) ([Table 2](#t0002){ref-type="table"}). The risk of soft-tissue sarcoma in the MoM cohort was the same than that in the non-MoM cohort (RR 0.9, CI 0.4--2.0, p = 0.8).

Incidence of basalioma in the MoM cohort was higher than in the general Finnish population (SIR 1.2, CI 1.1--1.4; p \< 0.001) ([Table 3](#t0003){ref-type="table"}) and also higher than that of the non-MoM cohort (RR 1.2, CI 1.0--1.4, p = 0.02).

The SIR of skin melanoma in the MoM cohort was 1.1 (CI 0.8--1.5) and that in the non-MoM cohort was 1.2 (CI 1.0--1.5) ([Table 3](#t0003){ref-type="table"}). Risk of melanoma in the MoM cohort was not higher than that in the non-MoM cohort (RR 0.9, CI 0.6--1.4, p = 0.7).

Discussion {#s0006}
==========

We found that the overall midterm risk of cancer was not increased in patients treated with MoM hip implants when compared wit the general Finnish population in midterm follow-up. This is in line with previous short term follow-up studies on second-generation MoM hip implants (Mäkelä et al. [@CIT0014], Smith et al. [@CIT0029], Brewster et al. [@CIT0003], Lalmohamed et al. [@CIT0011], Mäkelä et al. [@CIT0015]). The slightly lower overall risk of cancer in the MoM group can be influenced by the fact that MoM patients tend to be young and possibly healthier than the average population, which might cause some selection bias. A recent study from Slovenia including only THAs found a slightly higher risk of overall cancer in patients treated with MoM bearing when compared with the general population or the non-MoM patients (Levasic et al. [@CIT0013]). In that study the specific cancer types that had higher prevalence in the MoM cohort compared with the general population were skin cancers excluding melanoma and prostate cancer. Comparably, we found higher risk for basalioma in our MoM cohort. This confirmation of our results from another country is an interesting finding, and needs further research. The study cohort size in the study by Levasic et al. was smaller than ours (338 MoM THAs). Prostate cancer risk was not increased in the MoM cohort in our study when compared with the general Finnish population.

Although MoM hip implants are associated with local pseudotumors, adverse local tissue reactions (ALTR), and possible genetic alterations, based on earlier literature it seems that the risk for systemic tumors is not elevated after MoM THA (Case et al. [@CIT0005], Pandit et al. [@CIT0021], Ollivere et al. [@CIT0018], Langton et al. [@CIT0012]). Our findings are in line with these studies. Sarhadi et al. ([@CIT0026]) studied DNA extracted from periprosthetic tissues of 20 MoM patients undergoing hip revision surgery because of ALTR. They found genetic alterations in 6 patients and a liposarcoma in 1 patient.

In our previous short-term follow-up study of this same study population the risk of soft-tissue sarcomas was elevated in the MoM group compared twith the non-MoM-group (Mäkelä et al. [@CIT0015]). Furthermore, in that study all sarcomas were diagnosed during the last 4 years of the follow-up, raising a concern that during longer follow-up soft-tissue sarcomas might be overrepresented in the MoM cohort and that there might be a causative relationship between metal wear debris and soft-tissue sarcomas. However, in the current study only 1 additional soft tissue sarcoma was observed during the additional follow-up years 2012--14, and the incidence was similar in the MoM patient population compared with the general Finnish population and similar to the risk in the non-MoM group. Nonetheless, the overall number of sarcomas is small and we plan to report further follow-up. To our knowledge, there are no other studies reporting increased incidence of soft-tissue sarcomas in patients treated with metal-on-metal hip implants.

Incidence of basalioma was higher in the MoM cohort than in the non-MoM cohort and also increased when compared with the Finnish population. A similar finding has previously been reported only with conventional total hip replacements (Brewster et al. [@CIT0003]). The majority of the previous studies on MoM hip implants either exclude non-melanoma skin cancer or include basaliomas in the category of other skin cancers and the data on basalioma incidence in patients treated with MoM implants is limited (Visuri et al. [@CIT0034], Smith et al. [@CIT0029], Lalmohamed et al. [@CIT0011]). Due to its benign nature, basalioma is traditionally not included in the official national cancer statistics. In Finland only the first basalioma for each person is recorded in the Finnish Cancer Registry (Pukkala et al. [@CIT0025]). This may bias our results since patients treated with HRA are generally younger than patients treated with conventional THA, and it may therefore be more likely for them to be diagnosed with basalioma for the first time during our follow-up.

We found that the incidence of skin melanoma was not elevated in the MoM cohort compared with the general Finnish population. Earlier studies have found conflicting evidence concerning conventional non-MoM THAs' association with melanoma incidence. Some studies have reported higher melanoma incidence in patients treated with non-MoM implants than in the general population (Nyrén et al. [@CIT0017], Olsen et al. [@CIT0019], Visuri et al. [@CIT0033], [@CIT0034]) while others have found no difference (Visuri et al. [@CIT0035], Levasic et al. [@CIT0013]). No increase in the risk of melanoma was found for patients treated with a MoM resurfacing device (Brewster et al. [@CIT0003]).

The study by Brewster et al. ([@CIT0003]) found an increased risk of multiple myeloma and other immunoproliferative neoplasms in THA patients during the first 4 years after arthroplasty. However, their study did not differentiate MoM bearings from other types of bearings and the study also included patients with rheumatic conditions, which are known to increase the risk of immunoproliferative neoplasms (Isomäki et al. [@CIT0010]). Our study found no excess risk of myeloma in the MoM hip implant patients.

We acknowledge that our study has several limitations. First, as with all registry-based studies there is a possibility of a selection bias. Registry-based studies have the advantage of reporting results from a large patient group and reporting so-called "real world data" but the disadvantage of possible confounding by indication (Freemantle et al. [@CIT0009]). That is, the patients selected for THA or HRA may be for example healthier than the average population. Ideally this could be avoided by randomized controlled studies. Second, we did not have any blood metal ion measurements or imaging findings of the patients. It is theoretically possible that higher cancer risk might be associated with higher ion levels and our study is not able to detect such a subgroup. However, the findings of the meta-analysis by Christian et al. ([@CIT0006]) suggest that the concentrations and doses of Co/Cr required to induce a genotoxic or tumorigenic outcome are much higher than the systemic Co/Cr concentrations typically present in MoM hip implant patients. Third, even though our follow-up time now reaches the midterm point, genetic alterations might still happen or manifest later. In a recent meta-analysis Pijls et al. ([@CIT0023]) reported a higher risk of mortality in patients with MoM THA compared with patients with non-MoM THA when the follow-up exceeded 10 years. No difference was noted with shorter follow-up. Considering this we plan to report long-term results from this same population.

In summary, patients treated with MoM hip implants had a comparable cancer risk to patients treated with non-MoM hip implants and the general Finnish population. They did not have increased risk for soft-tissue sarcoma or skin melanoma. Only the incidence for basalioma was increased in the MoM cohort compared with the non-MoM cohort and compared with the general population.
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